June 18, 2003
German drugmaker Schering said on Wednesday it had completed recruitment for a trial on its multiple sclerosis drug Betaferon intended to explore its efficacy in patients with early signs of the disease.
Schering said in a statement more than 450 patients from 98 centres in 20 countries had started treatment in the two-year Phase III study, adding it would release results of the study by mid-2005.
The patients will be given high doses of Betaferon at frequent intervals.
The study seeks to explore the possibility of postponing the development
of multiple sclerosis in patients at high risk of contracting the disease,
which is characterised by the loss of fatty tissue around nerve fibres
in the brain and spinal cord.
Copyright © 2003, Reuters News Service